StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, Maxim Group upgraded shares of Galmed Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, July 24th.
Galmed Pharmaceuticals Trading Down 1.5 %
Institutional Trading of Galmed Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. purchased a new stake in Galmed Pharmaceuticals in the 1st quarter worth about $42,000. Raymond James Financial Services Advisors Inc. raised its position in Galmed Pharmaceuticals by 158.9% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 38,856 shares during the period. Finally, Millennium Management LLC raised its position in Galmed Pharmaceuticals by 372.3% in the 2nd quarter. Millennium Management LLC now owns 50,748 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 40,003 shares during the period. 20.89% of the stock is owned by hedge funds and other institutional investors.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
- Five stocks we like better than Galmed Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Which Wall Street Analysts are the Most Accurate?
- MarketBeat Week in Review – 9/11 – 9/15
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.